Aimee Bence Lin

1.8k total citations · 1 hit paper
42 papers, 977 citations indexed

About

Aimee Bence Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Aimee Bence Lin has authored 42 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Aimee Bence Lin's work include Lung Cancer Treatments and Mutations (16 papers), DNA Repair Mechanisms (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Aimee Bence Lin is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), DNA Repair Mechanisms (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Aimee Bence Lin collaborates with scholars based in United States, Spain and Japan. Aimee Bence Lin's co-authors include Richard P. Beckmann, Scott M. Hynes, Samuel McNeely, David S. Hong, Ji Lin, Johanna C. Bendell, Suzanne F. Jones, Howard A. Burris, Jeffrey R. Infante and Keunchil Park and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Aimee Bence Lin

40 papers receiving 970 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers

Aimee Bence Lin

ONCOL

PRM

Lisa Malburg United States

Smruthi Vijayaraghavan United States

Kelly Waldeck Australia

Emmy D.G. Fleuren Netherlands

Ulrike Tontsch-Grunt Austria

Suso Platero United States

Raul Ayala United States

François Ringeisen France

Allison Marlow United States

Ahrum Min South Korea

Lisa Malburg United States

Aimee Bence Lin

405 ×0.6

ONCOL

493 ×0.8

181 ×0.7

PRM

99 ×0.7

48 ×0.6

Citations per year, relative to Aimee Bence Lin Aimee Bence Lin (= 1×) peers Lisa Malburg

Countries citing papers authored by Aimee Bence Lin

Since Specialization

Citations

This map shows the geographic impact of Aimee Bence Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimee Bence Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimee Bence Lin more than expected).

Fields of papers citing papers by Aimee Bence Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimee Bence Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimee Bence Lin. The network helps show where Aimee Bence Lin may publish in the future.

Co-authorship network of co-authors of Aimee Bence Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Aimee Bence Lin. A scholar is included among the top collaborators of Aimee Bence Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimee Bence Lin. Aimee Bence Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paweletz, Cloud P., Alison M. Urvalek, Kavita S. Garg, et al.. (2025). Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. Clinical Cancer Research. 31(12). 2406–2412.

Rayens, Emily, Lina S. Sy, Lei Qian, et al.. (2025). Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Annals of the Rheumatic Diseases. 84(6). 960–969. 1 indexed citations

Cheng, Ying, Herbert H. Loong, Caicun Zhou, et al.. (2024). Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.. Journal of Clinical Oncology. 42(23_suppl). 214–214. 1 indexed citations

Goto, Kōichi, Silvia Novello, Pilar Garrido, et al.. (2023). 490MO Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431. Annals of Oncology. 34. S1654–S1655. 1 indexed citations

Drilon, Alexander, Vivek Subbiah, Oliver Gautschi, et al.. (2022). Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. Journal of Clinical Oncology. 41(2). 385–394. 119 indexed citations breakdown →

Hong, David S., Kathleen N. Moore, Johanna C. Bendell, et al.. (2021). Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clinical Cancer Research. 27(7). 1864–1874. 37 indexed citations

Whale, Andrew, V. Karuppiah, Jaafar N. Haidar, et al.. (2021). 882 Selective affinity-enhanced T cell receptor bispecific targeting of KRAS G12D neoantigen driven cancers. SHILAP Revista de lepidopterología. A924–A924. 2 indexed citations

Goto, Kōichi, J. Wolf, Yasir Y. Elamin, et al.. (2021). FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).. Journal of Thoracic Oncology. 16(3). S228–S229. 5 indexed citations

Moore, Kathleen N., David S. Hong, Manish R. Patel, et al.. (2021). A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Targeted Oncology. 16(5). 569–589. 20 indexed citations

10.

Hong, David S., Kathleen N. Moore, Manish R. Patel, et al.. (2018). Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clinical Cancer Research. 24(14). 3263–3272. 62 indexed citations

11.

Patnaik, Amita, Michael S. Gordon, Frank Tsai, et al.. (2018). A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. 82(3). 407–418. 45 indexed citations

12.

Lowery, Caitlin D., Michele Dowless, Wayne Blosser, et al.. (2017). The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma. Clinical Cancer Research. 23(15). 4354–4363. 53 indexed citations

13.

Laquente, Berta, José A. López-Martín, Donald Richards, et al.. (2017). A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 17(1). 137–137. 53 indexed citations

14.

Byers, Lauren A., et al.. (2017). P2.06-028 A Phase 2 Study of Prexasertib in Patients with Extensive Stage Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). S1088–S1089. 3 indexed citations

15.

Infante, Jeffrey R., Amita Patnaik, Claire F. Verschraegen, et al.. (2017). Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 79(2). 315–326. 29 indexed citations

16.

Hong, David S., Jeffrey R. Infante, Filip Jankú, et al.. (2016). Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. Journal of Clinical Oncology. 34(15). 1764–1771. 118 indexed citations

17.

Calvo, Emiliano, Fadi Braiteh, Daniel D. Von Hoff, et al.. (2016). Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. Oncology. 91(5). 251–260. 33 indexed citations

18.

Scagliotti, Giorgio V., Jin Hyoung Kang, David C. Smith, et al.. (2016). Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs. 34(5). 625–635. 55 indexed citations

19.

Doi, Toshihiko, Takayuki Yoshino, Kohei Shitara, et al.. (2015). Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. Anti-Cancer Drugs. 26(10). 1043–1053. 24 indexed citations

20.

Calvo, Emiliano, Victor J. Chen, Mark S. Marshall, et al.. (2014). Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. Investigational New Drugs. 32(5). 955–968. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact